Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data

Dyne Therapeutics (DYN) is back in focus after the company kicked off its Phase 3 HARMONIA trial for zeleciment basivarsen in myotonic dystrophy type 1, alongside fresh long term data from its Duchenne program.

See our latest analysis for Dyne Therapeutics.

Dyne Therapeutics’ recent HARMONIA Phase 3 launch and fresh DELIVER data arrive after a volatile stretch, with a 7 day share price return of 18.82% and a 1 year total shareholder return of 52.02%. This suggests momentum has recently picked up despite earlier pullbacks.

If this neuromuscular update has you looking more broadly at drug development, it could be a good time to scan 34 healthcare AI stocks as potential next ideas on your research list.

With Dyne still loss making, trading at US$18.06 and screens flagging an intrinsic discount, the key question is whether recent clinical wins leave upside on the table or whether the market is already pricing in future growth.

DCF signals a large valuation gap at current price

Our DCF model estimates Dyne Therapeutics’ future cash flow value at $130.41 per share, compared with the last close of $18.06. On that basis, the shares screen as heavily undervalued on projected cash generation.

The SWS DCF model projects a stream of future cash flows and discounts them back to today using a required rate of return. It aims to estimate what those future dollars could be worth in present terms. This approach is often used for early stage or loss making biotech names where earnings and revenue are not yet meaningful, as is the case for Dyne, which reported $0 revenue and a net loss of $446.214m.

For a clinical stage neuromuscular company that is forecast to remain unprofitable over the next 3 years and is expected to have no revenue next year, a cash flow based approach focuses on long term potential rather than current income statement figures. That can produce a wide gap between model value and market price, particularly when the company is still funding operations with higher risk sources of capital and shareholders have recently experienced substantial dilution.

Look into how the SWS DCF model arrives at its fair value.

Result: DCF Fair value of $130.41 (UNDERVALUED)

However, you still have to weigh clinical trial risk and the reality that Dyne remains loss making, with any financing needs potentially affecting existing shareholders.

Find out about the key risks to this Dyne Therapeutics narrative.

Another view on valuation

That big $130.41 DCF fair value is eye catching, but one model is never the whole story. Dyne trades on a P/B of 3.1x, which is above the US Biotechs industry at 2.7x yet below a 9.4x peer average. So is the real risk that expectations are already mixed in?

See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Dyne Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With all of this in mind, does the balance of risks and rewards here match your own conviction, or feel a bit off? If you want to move quickly from headline to hard data, take a closer look at 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If this has sharpened your thinking on Dyne, do not stop here. Broadening your watchlist now can help you spot the next opportunity early.

• Target potential mispricings by reviewing companies our screener flags as 47 high quality undervalued stocks with solid fundamentals backing up the numbers.
• Strengthen your portfolio’s foundation by focusing on businesses highlighted in our solid balance sheet and fundamentals stocks screener (41 results) that may better withstand financial shocks.
• Hunt for fresh names before they are widely followed by checking our screener containing 25 high quality undiscovered gems packed with lesser known companies that still pass quality checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com